Generex Biotechnology Announces
Webcast and Invites All Shareholders to See and Listen to the
Corporate Presentation from the 21st Annual H.C. Wainwright Global
Healthcare Investment Conference
MIRAMAR, FL -- September 12, 2019 -- InvestorsHub NewsWire
-- Generex Biotechnology Corporation (GNBT) is pleased to announce
that the presentation delivered by Joe Moscato, President &
Chief Executive Officer and Richard Purcell, Senior Vice President
of Research to the H.C. Wainwright Global Healthcare Investment
Conference on Monday September 9, 2019 is now available as a
webcast. Mr. Moscato and Mr. Purcell presented the Generex
corporate strategy and operating plan, ongoing plans for up-listing
GNBT to Nasdaq, and the exciting news about the pending acquisition
of ALTuCELL and partnerships with Arizona Endocrinology Center and
Paradise Valley Family Medicine to advance the treatment and
management of diabetes through the NuGenerex end-to-end model for
integrated disease management.
Mr. Moscato stated, “The partnerships we have established with
the physician groups in Arizona under the banner of NuGenerex
Health provide the platform for the future of Generex. We are
re-establishing our diabetes franchise with our new model for
integrated, comprehensive care with 65,000 patients, 25,000 of whom
are insulin dependent. To make our model easy to understand, start
with the complex, chronic patient, who accounts for the majority of
healthcare costs in the U.S. With a focus on rebuilding the
doctor/patient relationship we partner with specialists to provide
ancillary business and clinical services through an MSO partnership
with the physician groups; our MSO partners receive discount codes
for NuGenerex products and services; we acquire companies like our
new partner ALTuCELL to provide products and services that can be
used by the physicians to take care of their patients; with the
captive patient population to whom we are providing comprehensive
specialty and primary care, NuGenerex Health intends to obtain to
provide the end-to-end solutions under Medicare Advantage HMO
contracts.”
Mr. Purcell said, “As announced on Monday, we so pleased to have
the opportunity to acquire ALTuCELL, which has superior, patented
microencapsulation technology for cell therapy, and which has 5
years of safety data in humans. The microcapsules will be available
for licensing to biotech company partners who are seeking a
solution for immune rejection and implantation safety for their
cellular therapies. The value of cell encapsulation technology is
well recognized, as demonstrated by the recently announced
acquisition of Semma Therapeutics by Vertex, so we are very happy
to have ALTuCELL as part of the NuGenerex family of companies.
Additionally, ALTuCELL’s proprietary Altsulin® (microencapsulated
Sertoli Cells) cellular therapy offers a potential cure for Type I
diabetes; in the pre-clinical translational research in animals
from rodents to primates, the microencapsulated Sertoli Cells not
only activated pancreatic islet cells to secrete insulin, but also
a rebalancing of the autoimmune response. We look forward to
working with ALTuCELL CEO Gary Harlem and his team to become a
leader in the treatment of diabetes, and we invite you to join the
webcast at http://wsw.com/webcast/hcw5/gnbt/index.aspx.”
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company
with end-to-end solutions for patient centric care from rapid
diagnosis through delivery of personalized therapies. Generex is
building a new kind of healthcare company that extends beyond
traditional models providing support to physicians in an MSO
network, and ongoing relationships with patients to improve the
patient experience and access to optimal care.
In addition to advancing a legacy portfolio of immune-oncology
assets, medical devices, and diagnostics, the Company is focused on
an acquisition strategy of strategic businesses that complement
existing assets and provide immediate sources of revenue and
working capital. Recent acquisitions include a management services
organization, a network of pharmacies, clinical laboratory, and
medical device companies with new and approved products.
Our newly formed, wholly-owned subsidiary, NuGenerex
Distribution Solutions (NDS), integrates our MSO network with a
pharmacy network, clinical diagnostic lab, durable medical
equipment company (DME-IQ) and dedicated call center.
About Olaregen Therapeutix
Olaregen Therapeutix, Inc. is a regenerative medicine company
focused on the development, manufacturing and commercialization of
products that fill unmet needs in the current wound care market.
Generex aims to provide advanced healing solutions that
substantially improve medical outcomes while lowering the overall
cost of care. Olaregen's first product
introduction, Excellagen (flowable dermal
matrix) is a topically applied product for dermal wounds and other
indications. Excellagen is a FDA 510K cleared
device for a broad array of dermal wounds, including partial and
full thickness wounds, pressure ulcers, venous ulcers, diabetic
ulcers, chronic vascular ulcers, tunneled/undermined wounds,
surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser
surgery, podiatric, wound dehiscence), trauma wounds (abrasions,
lacerations, second-degree burns and skin tears) and draining
wounds, enabling Olaregen to
market Excellagen in multiple vertical markets.
Additionally, Excellagen can serve as an
Enabling Delivery Platform for pluripotent stem cells,
antimicrobial agents, small molecule drugs, DNA-Based Biologics,
conditioned cell media and peptides. Olaregen's initial focus will
be in advanced wound care including diabetic foot ulcers (DFU),
venous leg ulcers and pressure ulcers. Future products focusing on
innovative therapies in bone and joint regeneration comprise the
current pipeline. Generex's mission is to become a significant
force in regenerative medicine and advance the science of
healing.
About our Service-Disabled Veteran-Owned Small Business
(SDVOSB)
This a Service-Disabled Veteran-Owned Small Business (SDVOSB) that
specializes in the sale, marketing, and distribution of innovative
medical products through a nationwide network of veteran owned
distribution services.
About Pantheon Medical
Pantheon Medical is a manufacturer of a physician friendly,
“all-in-one”, integrated kit that includes plates, screws, and
tools required for orthopedic surgeons and podiatrists conducting
foot and ankle surgeries. Generex is developing and submitting
several new product lines to the FDA which will include cannulated
surgical screws, plates, and implants.
About MediSource Partners
MediSource Partners is a 10-year-old private company, currently
contracted with over 25 vendors (including Pantheon Medical) for
nationwide distribution of implants and devices for spine, hips,
knees, foot, ankle, hand, and wrist surgeries. Additional product
lines include biologics (blood, bone, tissue, stem cells), durable
medical equipment, and soft goods. Generex also supplies kits to
process bone marrow aspirates and platelet rich plasma biologics at
the time of surgery.
Cautionary Note Regarding Forward-Looking
Statements
This release and oral statements made from time to time by
Generex representatives in respect of the same subject matter may
contain "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by introductory words such as "expects," "plan,"
"believes," "will," "achieve," "anticipate," "would," "should,"
"subject to" or words of similar meaning, and by the fact that they
do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product
development activities, clinical studies, regulatory submissions
and approvals, and similar operating matters. Many factors may
cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to
time in the reports filed by Generex with the Securities and
Exchange Commission, which should be considered together with any
forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing
undue reliance on such statements. Generex undertakes no obligation
to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.
Generex claims the protection of the safe harbor for
forward-looking statements that is contained in the Private
Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Generex Biotechnology (CE) (USOTC:GNBT)
Historical Stock Chart
From Mar 2023 to Mar 2024